Breyanzi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0055/G	This was an application for a group of variations. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.c - Changes in the manufacturing process of	25/04/2025	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation				
II/0043/G	This was an application for a group of variations. Extension of indication for Breyanzi to include treatment of adult patients with 3rd line + follicular lymphoma (FL) based on final results from the pivotal study JCAR017-FOL-001 (FOL-001, TRANSCEND-FL). This is a phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with relapsed or refractory (r/r) follicular Lymphoma (FL) or marginal zone lymphoma (MZL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is also updated in accordance. Version 5.1 of the RMP was also submitted. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters	30/01/2025	12/03/2025	SmPC and PL	Please refer to Scientific Discussion 'Breyanzi -H-C-004731-II-0043G

	and/or limits of the finished product - Tightening of specification limits C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IB/0051	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	21/02/2025	n/a		
IB/0053	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	19/12/2024	n/a		
IB/0054	B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	17/12/2024	n/a		
IB/0047	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	13/12/2024	n/a		
IB/0050/G	This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	03/12/2024	n/a		
IAIN/0052	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -	20/11/2024	12/03/2025	Annex II and	

	Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing			PL	
IB/0046/G	This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	13/11/2024	n/a		
IAIN/0045/G	This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	26/09/2024	n/a		
PSUSA/10990 /202402	Periodic Safety Update EU Single assessment - lisocabtagene maraleucel / lisocabtagene maraleucel	05/09/2024	n/a		PRAC Recommendation - maintenance
IB/0042/G	This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of	04/09/2024	n/a		

	the AS - Other variation B.I.c.1.z - Change in immediate packaging of the AS - Other variation				
IAIN/0044	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	03/09/2024	12/03/2025	SmPC, Annex II and PL	
II/0037/G	This was an application for a group of variations. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product B.I.e.2 - Introduction of a post approval change management protocol related to the AS	25/07/2024	n/a		Not applicable
IB/0041	B.I.c.1.z - Change in immediate packaging of the AS - Other variation	18/07/2024	n/a		
II/0036/G	This was an application for a group of variations. Grouped application comprising two variations as follows: C.I.4 – Update of sections 4.4 of the SmPC in order to add immune effector cell-associated neurotoxicity syndrome (ICANS) and ICE scoring in the table for neurologic adverse reaction and update of section 4.8 of the SmPC to add immune effector cell-associated neurotoxicity syndrome (ICANS) as an adverse drug reaction (ADR) with a "not known" frequency based on the cumulative review of MAH safety database and literature. The Package Leaflet is updated accordingly. An updated RMP version 4.1 has been provided including the relevant changes in	27/06/2024	27/09/2024	SmPC, Annex II and PL	Not applicable For more information, please refer to the Summary of Product Characteristics.

	accordance with the scope of this procedure. In addition, the MAH took this opportunity to introduce editorial changes and administrative updates concerning the PIP product status in section 4.2 and 5.1 of the SmPC. A.6 – To include the ATC Code L01XL08 in section 5.1 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data A.6 - Administrative change - Change in ATC Code/ATC Vet Code				
IB/0039	B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	22/05/2024	n/a		
IB/0038	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	11/04/2024	n/a		
PSUSA/10990 /202308	Periodic Safety Update EU Single assessment - lisocabtagene maraleucel / lisocabtagene maraleucel	07/03/2024	n/a		PRAC Recommendation - maintenance
II/0032	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	22/02/2024	n/a		
IB/0035	B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits	12/01/2024	n/a		

IB/0030/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	21/12/2023	n/a		
IB/0031	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	19/12/2023	n/a		
II/0026/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method	14/12/2023	n/a		

II/0018/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	14/12/2023	27/09/2024	Annex II	The Annex II has been updated to include the new manufacturer of the biological active substance(s) Celgene Corporation.
IB/0029	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process	24/11/2023	n/a		

	of the AS				
IB/0033	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	06/11/2023	n/a		
IB/0027/G	This was an application for a group of variations. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation	19/10/2023	n/a		
II/0028/G	This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	12/10/2023	n/a		
II/0019	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The	12/10/2023	n/a		

	change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product				
II/0021	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	14/09/2023	n/a		
II/0014	Update of section 4.8 and 5.1 of the SmPC in order to update efficacy information based on final results from studies 017001 and JCAR-017-BCM-001 listed as obligations in the Annex II. These studies aimed to further characterise the long-term efficacy and safety of Breyanzi in patients treated with relapsed or refractory DLBCL, PMBCL, FL3B after two or more lines of systemic therapy. Study 017001 is a phase 1, open-label, single-arm, multicohort, multicenter, seamless design trial, while study JCAR-017-BCM-001 is a phase 2, open-label, single-arm, multicohort, multicenter trial. The Annex II is updated accordingly. The RMP version 3.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/09/2023	27/09/2024	SmPC and Annex II	The efficacy information of the Product Information has been updated with the most recent available efficacy data indicating overall consistency with the previous data available. For more information, please refer to the Summary of Product Characteristics.
II/0003	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The	14/09/2023	n/a		

	change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product				
IB/0023	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	12/09/2023	n/a		
PSUSA/10990 /202302	Periodic Safety Update EU Single assessment - lisocabtagene maraleucel / lisocabtagene maraleucel	31/08/2023	n/a		PRAC Recommendation - maintenance
IB/0025	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	02/08/2023	n/a		
IAIN/0024/G	This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes	18/07/2023	n/a		

	do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP				
IB/0022	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	07/07/2023	n/a		
II/0013/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS	22/06/2023	n/a		
IB/0017/G	This was an application for a group of variations.	20/06/2023	n/a		

	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer				
IB/0015/G	This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	08/05/2023	n/a		
II/0005	Extension of indication to include treatment of adult patients with Second-line (2L) Transplant Intended (TI) Large B-Cell Lymphoma (LBCL) for BREYANZI, based on interim analyses from pivotal study JCAR017-BCM-003; this is a global randomized multicentre Phase III Trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed	30/03/2023	28/04/2023	SmPC, Annex II and PL	Please refer to Scientific Discussion 'Breyanzi-H-C-4731-II-0005'

	or refractory aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM); As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The annex II and Package Leaflet is updated in accordance. The MAH also took the opportunity to implement editorial changes in line to the core SmPC. Version 2.4 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IB/0016	B.II.f.z - Stability of FP - Other variation	21/04/2023	n/a		
PSUSA/10990 /202208	Periodic Safety Update EU Single assessment - lisocabtagene maraleucel / lisocabtagene maraleucel	16/03/2023	n/a		PRAC Recommendation - maintenance
II/0009	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	23/02/2023	n/a		
II/0007/G	This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	23/02/2023	n/a		

	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol				
IB/0011/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	17/01/2023	n/a		
II/0004	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	15/12/2022	n/a		
IB/0008	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	29/11/2022	n/a		
II/0002	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	21/07/2022	n/a		

IB/0001	B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation	06/05/2022	n/a		